Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

  • STATUS
    Recruiting
  • End date
    Nov 17, 2024
  • participants needed
    262
  • sponsor
    Pfizer
Updated on 20 September 2022
pemetrexed

Summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Description

B9991046 is a master protocol that will consist of sub-studies from the following parent

studies

B9991001 - NCT02603432 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991

Details
Condition Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
Treatment Pemetrexed, Avelumab, Utomilumab, Axitinib, Talazoparib, PF04518600, Lorlatanib, CMP 001
Clinical Study IdentifierNCT05059522
SponsorPfizer
Last Modified on20 September 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study
Participants must agree to follow the reproductive criteria
Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures

Exclusion Criteria

Female participants who are pregnant or breastfeeding
Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note